Interferon-gamma (IFN-γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa

References

• Amano M, Grant A, Kerdel FA. (2010). A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol, 49(8), 950–955.
   PubMed Web of Science ®Google Scholar
• Angel DE, Lloyd P, Carville K, Santamaria N. (2011). The clinical efficacy of two semi-quantitative wound-swabbing techniques in identifying the causative organism(s) in infected cutaneous wounds. Int Wound J, 8(2), 176–185.
   PubMed Web of Science ®Google Scholar
• Bechara FG, Sand M, Skrygan M, et al. (2012). Acne inversa: evaluating antimicrobial peptides and proteins. Ann Dermatol, 24(4), 393–397.
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. (2003). The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol, 3(7), 521–533.
   PubMed Web of Science ®Google Scholar
• Calmon-Hamaty F, Combe B., Hahne M., Morel J. (2011). Lymphotoxin alpha revisited: general features and implications in rheumatoid arthritis. Arthritis Res Ther, 13(4), 232.
   PubMed Web of Science ®Google Scholar
• Calmon-Hamaty F, Combe B, Hahne M, Morel J. (2011). Lymphotoxin alpha stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine, 53(2), 207–214.
   PubMed Web of Science ®Google Scholar
• Charles CA, Romanelli P, Martinez ZB, et al. (2009). Tumor necrosis factor–alfa in nonhealing venous leg ulcers. J Am Acad Dermatol, 60(6), 951–955.
   PubMed Web of Science ®Google Scholar
• Chiang EY, Kolumam GA, Yu X, et al. (2009). Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med, 15(7), 766–773.
   PubMed Web of Science ®Google Scholar
• Chowdhury F, Williams A, Johnson P. (2009). Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods, 340(1), 55–64.
   PubMed Web of Science ®Google Scholar
• Cosmatos I, Matcho A, Weinstein R, et al. (2013). Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol, 69(5), 819.
   PubMed Web of Science ®Google Scholar
• Danby FW, Jemec GB, Marsch W, von Laffert M. (2013). Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol, 168(5), 1034–1039.
   PubMed Web of Science ®Google Scholar
• DeFazio MV, Economides JM, King KS, et al. (2015). Outcomes after combined radical resection and targeted biologic therapy for the management of recalcitrant hidradenitis suppurativa. Ann Plast Surg, 77(2), 217–222.
   Web of Science ®Google Scholar
• Domenech C, Matarredona J, Escribano-Stable JC, et al. (2012). Facial hidradenitis suppurativa in a 28-year-old male responding to finasteride. Dermatology, 224(4), 307–308.
   PubMed Web of Science ®Google Scholar
• Dreno B, Khammari A, Brocard A, et al. (2012). Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol, 148(2), 182–186.
   PubMedGoogle Scholar
• Emelianov VU, Bechara FG, Glaser R, et al. (2012). Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol, 166(5), 1023–1034.
   PubMed Web of Science ®Google Scholar
• Eming SA, Krieg T, Davidson JM. (2007). Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol, 127, 514–525.
   PubMed Web of Science ®Google Scholar
• Eming SA, Martin P, Tomic-Canic M. (2014). Wound repair and regeneration: Mechanisms, signaling, and translation. Sci Trans Med, 6(265), 265sr266–265sr266.
   Web of Science ®Google Scholar
• Esmann S, Dufour DN, Jemec GB. (2010). Questionnaire-based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions. Br J Dermatol, 163(1), 102–106.
   Google Scholar
• Giatrakos S, Huse K, Kanni T, et al. (2013). Haplotypes of IL-12Rbeta1 impact on the clinical phenotype of hidradenitis suppurativa. Cytokine, 62(2), 297–301.
   PubMed Web of Science ®Google Scholar
• Gommerman JL, Browning JL. (2003). Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol, 3(8), 642–655.
   PubMed Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. (2010). Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol, 62(2), 205–217.
   PubMed Web of Science ®Google Scholar
• Haslund P, Lee RA, Jemec GB. (2009). Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol, 89(6), 595–600.
   PubMed Web of Science ®Google Scholar
• Hessam S, Sand M, Gambichler T, Bechara FG. (2015). Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol, 73(6), 998–1005.
   PubMed Web of Science ®Google Scholar
• Hofmann SC, Saborowski V, Lange S, et al. (2012). Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol, 66(6), 966–974.
   PubMed Web of Science ®Google Scholar
• Iizuka K, Chaplin DD, Wang Y, et al. (1999). Requirement for membrane lymphotoxin in natural killer cell development. Proc Natl Acad Sci USA, 96(11), 6336–6340.
   PubMed Web of Science ®Google Scholar
• Jahns AC, Killasli H, Nosek D, et al. (2014). Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients. APMIS, 122(9), 804–809.
   PubMed Web of Science ®Google Scholar
• Jemec GB. (2013). Predicting response to anti-TNF-alpha treatment in Hidradenitis suppurativa. Br J Dermatol, 168(2), 233.
   PubMed Web of Science ®Google Scholar
• Jemec GBE. (2012). Hidradenitis suppurativa. N Engl J Med 366(2), 158–164.
   PubMed Web of Science ®Google Scholar
• Kanni T, Tzanetakou V, Savva A, et al. (2015). Compartmentalized cytokine responses in hidradenitis suppurativa. PLoS ONE, 10(6), e0130522.
   PubMed Web of Science ®Google Scholar
• Kelly G, Sweeney CM, Tobin A-M, Kirby B. (2014). Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol, 53(10), 1186–1196.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. (2012). Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med, 157(12), 846–855.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. (2016). Two Phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med, 375(5), 422–434.
   PubMed Web of Science ®Google Scholar
• Kirsner R. (2010). Biological agents for chronic wounds. Am J Clin Dermatol, 11(1), 23–25.
   PubMed Web of Science ®Google Scholar
• Laffert Mv, Helmbold P, Wohlrab J, et al. (2010). Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol, 19(6), 533–537.
   PubMed Web of Science ®Google Scholar
• Lesage C, Adnot-Desanlis L, Perceau G, et al. (2012). Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa. Eur J Dermatol, 22(5), 640–644.
   PubMed Web of Science ®Google Scholar
• Li J, Chen J, Kirsner R. (2007). Pathophysiology of acute wound healing. Clin Dermatol, 25(1), 9–18.
   PubMed Web of Science ®Google Scholar
• Loots MA, Lamme EN, Zeegelaar J, et al. (1998). Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol, 111(5), 850–857.
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, et al. (2011). A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol, 165(2), 391–398.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Weigmann B, Finotto S, et al. (2002). The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med, 195(9), 1129–1143.
   PubMed Web of Science ®Google Scholar
• Ohmori Y, Schreiber RD, Hamilton TA. (1997). Synergy between Interferon-γ and Tumor Necrosis Factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB. J Biol Chem, 272(23), 14899–14907.
   PubMed Web of Science ®Google Scholar
• Randhawa HK, Hamilton J, Pope E. (2013). Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol, 149(6), 732–735.
   PubMed Web of Science ®Google Scholar
• Sadir R, Forest E, Lortat-Jacob H. (1998). The heparan sulfate binding sequence of Interferon-γ increased the on rate of the Interferon-γ-Interferon-γ receptor complex formation. J Biol Chem, 273(18), 10919–10925.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Emtestam L, Jemec GBE, Lapins J. (2009). Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161(4), 831–839.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Killasli H, Heilborn J, et al. (2010). Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol, 162(6), 1261–1268.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Hanni T, Yawalkar N, Hunger RE. (2011). Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol, 65(4), 790–798.
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Wilson CB. (2007). Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol, 96, 41–101.
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Hume DA. (2004). Interferon-γ: an overview of signals, mechanisms and functions. J Leukocyte Biol, 75(2), 163–189.
   PubMed Web of Science ®Google Scholar
• Sharon VR, Garcia MS, Bagheri S, et al. (2012). Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol, 92(3), 320–321.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, Laman JD, de Ruiter L, et al. (2012). Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol, 166(2), 298–305.
   PubMed Web of Science ®Google Scholar
• Van Rappard DC, Mekkes JR. (2012). Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions. Br J Dermatol, 167(1), 206–208.
   PubMed Web of Science ®Google Scholar
• Vazquez BG, Alikhan A, Weaver AL, et al. (2013). Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol, 133(1), 97–103.
   PubMed Web of Science ®Google Scholar
• Vila-del Sol V, Punzón C, Fresno M. (2008). IFN-γ-Induced TNF-α expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. J Immun, 181(7), 4461–4470.
   PubMed Web of Science ®Google Scholar
• Weinstein DA, Kirsner RS. (2010). Refractory ulcers: The role of tumor necrosis factor–α. J Am Acad Dermatol, 63(1), 146–154.
   PubMed Web of Science ®Google Scholar
• Yazdanyar S, Jemec GB. (2011). Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis, 24(2), 118–123.
   PubMed Web of Science ®Google Scholar